Skip to main content
Pfizer's Fragmin OK'd for pediatric symptomatic VTE
5/17/2019

Pfizer's Fragmin, or dalteparin sodium, was approved by the FDA to lessen the recurrence of symptomatic venous thromboembolism in pediatric patients at least 1 month old. The drug was first approved for adult patients with certain types of angina, deep vein thrombosis and symptomatic VTE.

Full Story: